Effectiveness and Safety of Recombinant Human Brain Natriuretic Peptide for the Treatment of Patients With Right Heart Failure Caused by Pulmonary Arterial Hypertension
10.3969/j.issn.1000-3614.2025.08.008
- VernacularTitle:重组人脑利钠肽治疗动脉型肺动脉高压所致右心衰竭的有效性及安全性研究
- Author:
Lixing HU
1
;
Qing ZHAO
1
;
Zhihui ZHAO
1
;
Qin LUO
1
;
Li DENG
1
;
Ping JIANG
1
;
Zhihong LIU
1
Author Information
1. 中国医学科学院 北京协和医学院 国家心血管病中心 阜外医院 呼吸与肺血管疾病诊治中心,北京 100037
- Publication Type:Journal Article
- Keywords:
pulmonary arterial hypertension;
right heart failure;
recombinant human brain natriuretic peptide;
effectiveness;
safety
- From:
Chinese Circulation Journal
2025;40(8):782-786
- CountryChina
- Language:Chinese
-
Abstract:
Objectives:To observe the effectiveness and safety of recombinant human brain natriuretic peptide(rhBNP)for the treatment of patients with right heart failure caused by pulmonary arterial hypertension(PAH).Methods:A total of 421 patients with right heart failure caused by PAH who were hospitalized in Fuwai Hospital from January 2019 to June 2024 were retrospectively included in this study.All patients were treated with rhBNP on top of conventional therapy.24 h urine volume,body weight,liver and renal function index,electrolyte,uric acid,red blood cell distribution width(RBCDW),cardiac function,blood pressure and heart rate before and after the treatment of rhBNP were compared.Clinical symptoms,signs and the occurrence of adverse events during treatment were also observed.Results:Compared with baseline,after treatment with rhBNP,the 24 h urine volume increased.The levels of body weight,transaminase,total bilirubin,direct bilirubin,uric acid,RBCDW,systolic blood pressure,heart rate,and N-terminal pro-B-type natriuretic peptide significantly decreased(all P<0.05).There were no statistically significant differences in the levels of serum creatinine,and tricuspid annular plane systolic excursion to pulmonary artery systolic pressure ratio(both P>0.05).Dyspnea and lower limbs edema were improved in 75.2%cases(227/302)and 66.9%cases(281/420)respectively.The incidence of adverse events and severe adverse events during rhBNP treatment were 1.2%(5/421)and 0.5%(2/421)respectively.Conclusions:Adding rhBNP on top of standard medication can effectively increase 24 h urine volume,reduce body weight,improve some prognostic indicators,improve the clinical symptoms and signs of heart failure without negatively affecting the renal function in right heart failure patients caused by PAH.Blood pressure should be closely monitored during the treatment process.
